依托泊苷。对其药效学和药代动力学特性以及在癌症联合化疗中的治疗潜力的综述。 - Suppr

Suppr

超能文献

Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

作者信息

Henwood J M, Brogden R N

机构信息

ADIS Drug Information Services, Manchester, England.

出版信息

Drugs. 1990 Mar;39(3):438-90. doi: 10.2165/00003495-199039030-00008.

DOI:10.2165/00003495-199039030-00008

PMID:2184009

Abstract

摘要

相似文献

Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Drugs. 1990 Mar;39(3):438-90. doi: 10.2165/00003495-199039030-00008.

Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect.

Cancer Chemother Pharmacol. 2011 Mar;67(3):597-603. doi: 10.1007/s00280-010-1357-2. Epub 2010 May 20.

Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).

Clin Cancer Res. 1997 May;3(5):719-25.

Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.

Lung Cancer. 2008 Nov;62(2):261-72. doi: 10.1016/j.lungcan.2008.03.008. Epub 2008 Apr 28.

Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study.

Cancer Chemother Pharmacol. 1999;44(6):461-8. doi: 10.1007/s002800051119.

[Pharmacokinetic aspects of oral administration of etoposide].

Klin Padiatr. 1998 Jul-Aug;210(4):159-64. doi: 10.1055/s-2008-1043872.

Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.

Clin Cancer Res. 2003 Jul;9(7):2504-9.

[Nedaplatin and etoposide combination chemotherapy in a patient with small cell carcinoma undergoing hemodialysis].

Gan To Kagaku Ryoho. 1999 Mar;26(4):527-30.

[Combination chemotherapy with carboplatin and etoposide against lung adenocarcinoma in a patient undergoing hemodialysis: a case report].

Gan To Kagaku Ryoho. 1993 Dec;20(15):2409-11.

Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient.

Pediatr Hematol Oncol. 2007 Sep;24(6):437-45. doi: 10.1080/08880010701451343.

引用本文的文献

A review on intrathecal administration of medications for leptomeningeal metastases in solid tumors.

Front Pharmacol. 2025 Feb 4;16:1472945. doi: 10.3389/fphar.2025.1472945. eCollection 2025.

Rapid Detection of the Anti-Tumor Drug Etoposide in Biological Samples by Using a Nanoporous-Gold-Based Electrochemical Sensor.

Molecules. 2024 Feb 28;29(5):1060. doi: 10.3390/molecules29051060.

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?

Front Pharmacol. 2023 Oct 26;14:1259908. doi: 10.3389/fphar.2023.1259908. eCollection 2023.

The protective effect of taurine, piracetam and vinpocetine on etoposide-induced inflammation and brain injury in the serum of female albino rats.

Ecancermedicalscience. 2023 Jan 23;17:1499. doi: 10.3332/ecancer.2023.1499. eCollection 2023.

Infusion of etoposide in the CA1 disrupts hippocampal immediate early gene expression and hippocampus-dependent learning.

Sci Rep. 2022 Jul 27;12(1):12834. doi: 10.1038/s41598-022-17052-y.

Repurposing of anti-lung cancer drugs as multi-target inhibitors of SARS-CoV-2 proteins: An insight from molecular docking and MD-simulation study.

Microb Pathog. 2022 Aug;169:105615. doi: 10.1016/j.micpath.2022.105615. Epub 2022 Jun 8.

A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response.

Nat Commun. 2022 Mar 31;13(1):1714. doi: 10.1038/s41467-022-29358-6.

Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play.

Transl Oncol. 2021 Oct;14(10):101169. doi: 10.1016/j.tranon.2021.101169. Epub 2021 Jul 6.

Substituted 4,5'-Bithiazoles as Catalytic Inhibitors of Human DNA Topoisomerase IIα.

J Chem Inf Model. 2020 Jul 27;60(7):3662-3678. doi: 10.1021/acs.jcim.0c00202. Epub 2020 Jun 22.

Intracerebroventricular drug administration.

Transl Clin Pharmacol. 2017 Sep;25(3):117-124. doi: 10.12793/tcp.2017.25.3.117. Epub 2017 Sep 15.

本文引用的文献

VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas.

Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1135-7.

An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer.

Oncology. 1980;37(3):149-51. doi: 10.1159/000225424.

A phase II study of oral VP-16-213 in non-seminomatous testicular cancer.

Eur J Cancer (1965). 1981 Feb;17(2):245-9. doi: 10.1016/0014-2964(81)90043-8.

Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.

Cancer Treat Rep. 1981 Jul-Aug;65(7-8):703-4.

Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.

Cancer Treat Rep. 1981 May-Jun;65(5-6):443-5.

VP16-213 as a single agent in advanced testicular tumors.

Eur J Cancer (1965). 1980 Sep;16(9):1193-7. doi: 10.1016/0014-2964(80)90178-4.

Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors.

Cancer Treat Rev. 1982 Jun;9 Suppl:79-84. doi: 10.1016/s0305-7372(82)80083-2.

Etoposide for therapy-resistant testicular tumors.

Cancer Treat Rev. 1982 Jun;9 Suppl:73-8. doi: 10.1016/s0305-7372(82)80082-0.

Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.

Cancer Treat Rep. 1982 Aug;66(8):1669-71.

Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.

Cancer Chemother Pharmacol. 1982;7(2-3):223-5. doi: 10.1007/BF00254555.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验